Pharsight

Cephalon patents expiration

1. Fentora patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8092832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering
Dec, 2024

(1 year, 3 months from now)

US8119158 CEPHALON Effervescent oral fentanyl dosage form and methods of administering fentanyl
Dec, 2024

(1 year, 3 months from now)

US7862832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering
Jun, 2028

(4 years from now)

US7862833 CEPHALON Effervescent oral opiate dosage forms and methods of administering opiates
Jun, 2028

(4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage

FENTORA family patents

Family Patents

2. Nuvigil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7132570 CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Dec, 2023

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil
Nov, 2023

(2 months from now)

US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(7 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Jun, 2024

(8 months from now)

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of NUVIGIL before it's drug patent expiration?
More Information on Dosage

NUVIGIL family patents

Family Patents

3. Provigil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil
Nov, 2023

(2 months from now)

US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(7 months from now)

Drugs and Companies using MODAFINIL ingredient

Market Authorisation Date: 24 December, 1998

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PROVIGIL before it's drug patent expiration?
More Information on Dosage

PROVIGIL family patents

Family Patents

4. Treanda patents expiration

TREANDA's oppositions filed in EPO
TREANDA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8445524 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609863 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8895756 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8791270 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US8609863

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(2 years from now)

US8791270

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(2 years from now)

US8895756

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(2 years from now)

US8883836 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(5 years from now)

US9533955 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(5 years from now)

US8669279 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(5 years from now)

US8344006 CEPHALON Liquid formulations of bendamustine
Sep, 2029

(5 years from now)

US9533955

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8445524

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8883836

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8669279

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8344006

(Pediatric)

CEPHALON Liquid formulations of bendamustine
Mar, 2030

(6 years from now)

US8436190 CEPHALON Bendamustine pharmaceutical compositions
Oct, 2030

(7 years from now)

US8436190

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE* (ODE*) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 March, 2008

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell...

Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)

How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage

TREANDA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic